Omega Diagnostics (UK) upgrades tuberculosis kit for Indian market:
This article was originally published in Clinica
Omega Diagnostics (UK) is increasing the sensitivity of its TB ELISA. The privately-held Scottish company is making the improvements - to aid in the diagnosis of difficult cases such as sputum-negative/TB-positive and extrapulmonary disease - at the request of the Indian Council of Medical Research (a government body). Omega hopes to secure development funding from the Scottish Office of the UK government and says an application for WHO trial funding is under review. The work is expected to take about a year. Omega already sells the kit throughout the Indian subcontinent around the Pacific Rim.
You may also be interested in...
ConMed Corp. is company of two halves ̶ general surgery and orthopedics – and is readying itself for a renewed assault on these two markets on the back of a technology pipeline, targeted acquisitions and a new growth-winning culture, says CFO Todd Garner.
Drug pricing and access issues expose the pharmaceutical sector especially acutely to calls for companies to meet ethical and social goals, alongside commercial ones. Digital is up-ending pharma’s processes, its workplaces and its consumers. R&D productivity is spluttering. Amid this turmoil, CEOs highlight company culture – the way an organization behaves – as a crucial ingredient for success. But what is a “right” culture? Organizational culture is neither static nor singular. It is continuously influenced by acquisitions, markets, new technologies and new generations. And pharma’s history suggests that culture change cannot happen without sufficient people change.